HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results – Interim analysis

Santam Chakraborty(Tata Medical Center), Debdeep Dey(University of Ghana), S. Mandal(Bose Institute), M. Dinesh(Tata Medical Center), Abha Kumari, Shagun Misra, Kishore Das, Subecha Bhushal(Tata Medical Center), C. Shamsudden(Tata Medical Center), Selvamani Backianathan(University of Tsukuba), Henry Finlay Godson, Sanjoy Chatterjee(Tata Medical Center), Subhash C. Gupta, Debashree Guha, Rajesh Balakrishan, Anurupa Mahata(Tata Medical Center), Rosina Ahmed(Tata Medical Center), Punita Lal, Patricia Solomon, Sandip Ganguly(Regeneron (United States))

Radiotherapy and Oncology

July 8, 2022

10.1016/j.radonc.2022.07.003

Cited by 42

Related Papers

Human papillomavirus in head and neck cancer in India: Current status and consensus recommendations

|South Asian Journal of Cancer|2017|48

Resource requirements and reduction in cardiac mortality from deep inspiration breath hold (DIBH) radiation therapy for left sided breast cancer patients: A prospective service development analysis

|Practical Radiation Oncology|2018|32

Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)—study protocol for a multicentre, randomized phase III trial

|Trials|2020|29

Oral cavity adjuvant therapy (OCAT) -a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity

|European Journal of Cancer|2022|29

Alleviating Morbidity From Locally Advanced Breast Cancer Using a Practical and Short Radiation Therapy Regimen: Results of the HYPORT Palliative Studies

|International Journal of Radiation Oncology*Biology*Physics|2023|22